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ECONOMIC AND OUTCOMES ISSUES IN GI
DISORDERS, DIABETES, ASTHMA, AND
OTHER DISORDERS
PGD.
THE EFFECTS OF COMMUNITY-BASED
PHARMACEUTICAL CARE SERVICES ON
ASTHMA-RELATED QUALITY OF LIFE
Boyd BJ. Rascati, KL, Lawson, KA
University of Texas at Austin College of Pharmacy,
Austin, TX, USA
Community pharmacy practice is evolving from a prod-
uct-oriented focus to an environment where pharmaceuti-
cal care services are provided in order to meet an overall
therapeutic goal (disease management). Specialized ser-
vices may contribute to positive therapeutic outcomes for
patients served and may improve patients' quality of life.
OBJECTIVE: The purpose of this study was to determine
the effects of specialized pharmaceutical care services for
adult asthmatic patients served in community pharmacy
settings on their health-related quality of life.
METHODS: Adult asthmatic patients received special-
ized pharmaceutical services for one year in 7 community
pharmacies located throughout Texas. All intervention
pharmacies were members of a pharmaceutical care net-
work that provided software, enabling pharmacists to
document interactions with patients. All study patients
were insured by Blue Cross/Blue Shield of Texas, patron-
ized an intervention pharmacy, were confirmed asthmat-
ics (by their physician), and were currently taking asthma
medication(s). Juniper's Asthma Quality of Life Ques-
tionnaire, which includes activity, symptom, emotion,
and exposure domains, was used to evaluate quality of
life changes.
RESULTS: A total of 25 patients completed quality of life
questionnaires over the course of the intervention period
and had pharmacist documentation. Quality of life scores
were compared before and during intervention periods.
When mean baseline overall quality of life scores were
compared to mean ending overall quality of life scores for
intervention patients, a statistically significant improve-
ment was found (t = -2.872; df = 20; p =0.009). Statis-
tically significant improvements were also observed in the
activity (t = -2.795; df = 20; p = 0.011) and symptom
(r = -2.913; df = 20; p = 0.009) domains.
CONCLUSIONS: While improved quality of life was as-
sociated with the pharmaceutical care intervention, fur-
ther research involving more patients is needed to ade-
quately determine the extent of benefits that specialized
pharmaceutical care services could provide.
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THE ECONOMIC IMPLICATIONS OF DECREASED
PATIENT ADHERENCE TO CO-PRESCRIBED
DICLOFENAC AND MISOPROSTOL
(CoRx-D&M) RELATIVE TO A
SINGLE·TABLET FORMULATION OF
DICLOFENAC/MISOPROSTOL (STF-D/M)
Goldstein JL', Stewart D2, Zabinski RAJ, Larson LR4
'University of Illinois, Chicago, IL, USA; -Brogan Inc., Toronto.
Canada; 3G. D. Searle & Co., Skokie, IL, USA; 4C1inTrial
Ovation, Highland Park, IL, USA
Since patient adherence is related to dosage schedules and
the number of medications prescribed, we questioned the
relative adherence to and the economic impact of CoRx-
D&M dispensed as separate agents versus ensured pa-
tient adherence with STF-D/M.
OBJECTIVE: Evaluate the economic implications of
changes in patient adherence.
METHODS: Data were extracted from a Canadian, time-
series database of patient-level pharmacy claims (15.8
million pharmacy claims, totaling C$459.3 milliorr' per
year). From 1/1/93 to 8/31/97, 4,880 CoRx-D&M pa-
tients were identified and 1,001 STF-D/M patients were
identified. Over a 56-month period, consecutive claims
were analyzed to determine relative adherence to each
regimen. The adherence results were entered into a deci-
sion analysis model to project economic outcomes.
RESULTS: Adherence gradually declined in the CoRx-
D&M group to 58% by the fifth diclofenac claim produc-
ing a weighted average adherence rate of 61 %. Therefore,
39% of patients received NSAIDs without misoprostol.
This contrasts with the 100% ensured adherence rate with
STF-D/M. Using standard rates of ulcer complications for
high-risk patients, the economic implications of the decline
in adherence results in an increase in health care costs from
$182.14 per patient per month (PPPM) (assuming 100%
adherence) to $191.45 PPPM (assuming 61% adher-
ence)-an incremental increase of $9.01 PPPM. If patients
receiving co-therapy had been receiving STF-D/M, health-
care costs would be reduced from $191.45 PPPM to
$188.86 PPPM-an incremental savings of $2.59 PPPM.
CONCLUSION: Removing the issue of patient non-
adherence that is seen with co-prescribed medications by
prescribing STF-D/M reduces the risk of NSAID-induced
GI complications and decreases overall health care costs.
PGDII
COST-UTILITY RELATION OF THE TREATMENT
OF DIABETIC FOOT LESION WITH HYPERBARIC
OXYGENE THERAPY VERSUS STANDARD
THERAPY
Kilburg A, Rychlik R, Rappenhoner B
Institute of Empirical Health Economics, Odenthal, Germany
Diabetes mellitus is a major and growing European
health problem at all ages and all countries. Diabetic an-
giopathy leads to chronic foot lesion and has a high risk
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of amputation. In clinical studies the effectiveness of Hy-
perbaric oxygene therapy of diabetic foot lesion was
proved. Hyperbaric oxygene therapy adjunctive to ther-
apy of diabetic food lesion can reduce anaerobic infec-
tions, improve blood supply and decrease ischemic dam-
age to nerves.
OBJECTIVE: This analysis centred around which of the
alternative therapies-standard therapy plus Hyperbaric
oxygene therapy and standard therapy alone-incurs the
best cost-effectiveness ratio. The comparison of costs and
benefits was made on the basis of a cost-effectiveness
analysis.
METHODS: A decision tree with four endpoints was
constructed: (1) successful therapy without amputations,
(2) small amputations, (3) major amputations with post
hospital treatment, and (4) major amputation with do-
mestic nursing. Data regarding the number and severity
of amputations underlying were taken from a clinical
study. Health care costs included in the model were all
medical costs (hospitalisation, surgical intervention, drug
costs, etc.) and indirect costs (absence from workplace,
retirement). The effectiveness was defined as avoided ma-
jor amputation. The following effectiveness rates were re-
vealed in the clinical study: population with adjunctive
Hyperbaric oxygene therapy, 0.9143; population only
with standard therapy, 0.6666. To improve the robust-
ness of the model, a sensitivity analysis was performed to
determine the influence of the efficacy on the incremental
cost-effectiveness ratio and the effects of of the costs of
post hospital treatment based on the incremental cost-
effectiveness ratio.
RESULTS: Standard therapy plus hyperbaric oxygene
therapy resulted in total costs of DM 45,141.00 per suc-
cessfully treated patient; standard therapy incurred total
costs of DM 52,392.00 per successfully treated patient.
CONCLUSION: The decision tree analysis reveals that
the treatment of diabetic foot lesion with adjunctive Hy-
perbaric oxygene therapy has the best incremental cost-
effectiveness ratio.
PGD.
COST-EFFECTIVENESS ANALYSIS OF
SCREENING OF TYPE II DIABETES
MELLITUS IN NONPREGNANT ADULTS
Hui RL, HayJW
School of Pharmacy, University of Southem Califomia, Los
Angeles, CA, USA
An estimated 8 million people in the U.S. have type II dia-
betes mellitus but are unaware of it.
OBJECTIVES: The study investigated the cost-effective-
ness of early detection of type II diabetes mellitus in vari-
ous risk groups.
METHODS: A Markov model was constructed based on
a societal perspective. There were 4 stages in the model:
(1) unknown diabetes status; (2) alive with diagnosed di-
abetes; (3) alive with diagnosed diabetes and related com-
plications, namely, retinopathy, blindness, neuropathy,
Abstracts
end-state renal disease, lower leg amputations, circula-
tory disorders; and (4) die secondary to diabetes or its
complications. Individuals could transit from one state to
another annually as a function of the predicted risk fac-
tors from epidemiological studies. The model assumed
that the patients who were screened positive for diabetes
and received treatment would have reduced rate of re-
lated complications as observed in the Diabetes Control
and Complications Trial. Health care costs included in
the model were screening tests, diabetes treatment cost,
complications and death. Various screening test thresh-
olds have also been considered in the model analysis.
RESULTS: Diabetes screening of the entire nonpregnant
adult US population yielded a cost-effectiveness ratio of
$24,600 per quality-adjusted life year. The cost-effective-
ness of screening only extremely obese patients with a
family history of diabetes was $10,083 per quality-
adjusted life year.
CONCLUSIONS: The study suggested that active screen-
ing for type II diabetes mellitus in high-risk individuals
was cost-effective. More information on the actual clini-
cal outcomes for oral diabetes medications is needed to
establish the precision of these estimates.
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PREDICTING HOSPITALIZATION OF PATIENTS
WITH DIABETES MELLITUS: AN APPLICATION
OF THE BAYESIAN DISCRIMINANT ANALYSIS
Bhattacharyya S
Procter & Gamble Pharmaceuticals, Cincinnati, OH, USA
OBJECTIVE: The main objectives of this paper were to
develop and subsequently test a Bayesian discrimination
model for the purpose of identifying both the personal
and the health care system characteristics predictive of
hospitalization for the treatment of diabetes or commonly
observed comorbidities associated with the disease,
METHODS: First, a Bayesian classification framework
was proposed to discriminate patients into two groups-
the high risk and the low risk. The model was then tested
by using a logit regression technique in order to estimate
the probability of one or more hospitalization events
among diabetes patients. The study used claims data ex-
tracted from the Hawaii Medical Service Association
(HMSA) Private Business Claims (PBS) files for the calen-
dar year 1995. Patients under 65 years were identified by
paid claims with ICD-9-CM diagnosis codes of 250.xx
which gave a sample size of 6,841.
RESULTS: Age, gender, various pharmacotherapy vari-
ables, presence of hypertension, hyperlipidemia, coronary
heart failure, multiple cardiovascular diseases, any com-
bination of commonly observed comorbidities, dialysis
services, and annual eye examination were highly predic-
tive of one or more hospitalization events. The model
showed a predictive power of almost 90%.
CONCLUSION: Multivariate discriminant analysis using a
logit regression model successfully (1) identified important
explanatory variables predictive of hospitalization, (2) as-
